Member Info for Moneymunch

Genflow Biosciences Eyes Pivotal Catalysts Across MASH, Glaucoma And Animal Health (video) htTps://share.google/bdFTrjDvSkam9IDYk

Genflow Biosciences (LON:GENF, OTCQB:GENFF, FRA:WQ5) is moving into a more consequential phase, with Dr Eric Leire outlining how promising dog study data, a potentially differentiated glaucoma approach and fresh non-dilutive funding are sharpening the company’s commercial and clinical trajectory. In this interview, he sets out where value could emerge next, from licensing discussions in animal health to late-stage MASH positioning and upcoming IP milestones.

KEY MOMENTS

00:24 – Promising dog study update.

00:42 – Glaucoma strategy targets retinal degeneration.

01:27 – Sarcopenia progress and platform shift.

01:45 – Funding boost and €4 million grant.

02:45 – Large market opportunities outlined.

05:06 – Near-term catalysts for investors.

06:42 – Glaucoma data and conference plans ahead.

07:03 – IP progress could strengthen valuation.

Genflow Biosciences is a biotechnology company developing therapies targeting age-related diseases, including MASH, glaucoma and sarcopenia.

GENFLOW BIOSCIENCES PLC LogoInternational Patent Publication

GENFLOW BIOSCIENCES PLC

Released 07:00:09 13 April 2026

RNS Number : 9012Z

Genflow Biosciences PLC

13 April 2026

13 April 2026

Genflow Biosciences Plc

International Patent Publication Expands Protection for SIRT6-Based Muscular Disease Program

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, is pleased to announce the international publication of its Patent Cooperation Treaty (PCT) application, WO 2026/062177 A1, entitled "Variants of Sirtuin 6 for the Treatment of Muscular Diseases."

The published PCT application relates to variants of SIRT6 for the prevention and treatment of muscular diseases, with particular focus on frailty syndrome and sarcopenia. The application describes compositions and methods involving SIRT6 variants, including nucleic acids, polypeptides, vectors and pharmaceutical compositions intended for use in muscular disease settings associated with loss of muscle mass and altered endocrine function of the muscle.

This international publication represents an important milestone in Genflow's intellectual property strategy and broadens the potential protection surrounding the Company's SIRT6 platform beyond longevity and metabolic applications. By advancing patent coverage into muscular diseases, Genflow is further strengthening the proprietary foundation of its platform while opening additional potential therapeutic pathways for development and partnering.

Strategic Significance

The publication enhances the visibility and scope of Genflow's IP estate at an international level. It supports the Company's strategy of building layered protection around the therapeutic use of SIRT6 variants across multiple age-related indications. The PCT publication also preserves Genflow's ability to pursue patent protection across multiple jurisdictions, supporting development flexibility and potential discussions with pharmaceutical and biotech partners. Taken together, this publication reinforces the depth of the Company's scientific platform and the continued expansion of its intellectual property backbone.

Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: "The international publication of this patent application marks another important step in the expansion of Genflow's intellectual property portfolio. By extending our SIRT6 platform into muscular diseases such as frailty and sarcopenia, we are continuing to build strategic protection around areas of high unmet need and significant relevance to healthy ageing. This publication further strengthens our position as we advance the development and potential partnering of our gene therapy platform."

Genflow Biosciences (LON:G.... - 2,342 followers

Follow

○

1h.

Advancing New Approaches for #Glaucoma

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is investigating the potential of #SIRT6 - a gene closely linked to longevity - in the treatment of glaucoma, a major cause of irreversible #blindness

Our #genetherapy platform is designed to target the underlying mechanisms of aging and DNA repair that drive disease progression.

By focusing on these root biological processes, we aim to go beyond symptom control and support more asting, vision-preserving outcomes.

#GENF #GENFF #Genflow #Aging #Biotech

Even better!!! ;-)))

Jeito Capital ("Jeito") is a leading independent global private equity firm dedicated to biopharma, which in April 2026 closed its second fund (Jeito II) with a record €1 billion (approximately US$1.2 billion). This fund focuses on investing in high-potential European and American biopharma companies addressing unmet medical needs and chronic diseases, with a specific interest in cell/gene therapies and, as noted in recent industry reporting, longevity science.

Here's hoping Genflow have caught their eye!!! Gla :-)

Prominent biotechnology investor Jeito Capital said Wednesday it closed a 1 billion euro, or $1.2 billion, venture fund to invest in a variety of early-stage drugmakers predominantly based in Europe.

The Jeito II Fund is “the largest raise ever achieved by a fully independent European fund dedicated to biopharma,” the Paris-based firm said in a statement. Jeito plans to support 15 to 20 clinical-stage drugmakers, supplying each with investments worth up to 150 million euros.

Launched in 2020, Jeito closed its first fund, a 534 million euro haul, a year later. The firm specifically focuses on what it calls “high-potential, clinical biopharma companies” and provides continued investments as those startups boost their value.

Jeito Capital, prominent biotech investor, raises $1.2B for next fund | BioPharma Dive https://share.google/Olfh4qCvHutS6HQQ7

Great work pickedpeck. Gl ;-)

Eric's interview on today's "very good & very promising results. Gla holders ;-)

Genflow CEO on promising SLAB trial data and next steps in dog trial

Published: 11:45 08 Apr 2026

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about encouraging results from the SLAB (Sarcopenia and Longevity in Aged Beagles) trial, highlighting sustained efficacy and safety following treatment.

Leire explained that one of the most significant findings is the durability of the therapy’s effects. Even three months after stopping treatment, the benefits observed in the dogs have been maintained. He noted: "We stopped administration three months ago... and that's exactly what we see, both in terms of safety and in terms of efficacy." This persistence is a key milestone for gene therapy, as it could shift treatment from a repeated or chronic approach to a potential one-time intervention.

The durability of response also has broader implications for other indications Genflow is pursuing. Leire indicated that the results support expectations for similar long-lasting effects in future applications, including MASH.

While clinical endpoints are already showing promising outcomes, the company is awaiting additional data from blood analyses and biopsies to complement these findings. These results could further validate the therapy’s impact, including potential reductions in biological age. The existing data has already enabled early discussions with animal health companies regarding potential partnerships.

Watch the full interview to learn more about how Genflow is advancing gene therapy innovation.

Genflow CEO on promising SLAB trial data and next steps in dog trial | LSE:GENF, OTCQB:GENFF htTps://share.google/6ayPCzmQY60P4DWDx

We've had an update within 2 months of the 12th Feb statement, but the trial was always planned to continue until June/July. It's all good imho and certainly doesn't deter any potential suitor from making an early move, and look forward to plenty more material newsflow from across the pipeline . Gla ;-)

28th January 2026

Dog Aging (GF-1004)

The ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers.

An initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects.

RNS Number : 6270Z

Genflow Biosciences PLC

08 April 2026

8 April 2026

Genflow Biosciences Plc

Genflow Reports Sustained Safety and Efficacy Three Months Post Dosing in SLAB Trial

Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, highlights continued positive safety and efficacy signals from its ongoing SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene therapy.

Follow-up observations conducted three months after the initial dosing period confirm that previously reported improvements have been maintained. No adverse events have been observed, and the therapy continues to demonstrate a favourable safety and tolerability profile in aged dogs.

These findings build on the Company's previously announced interim results (please see the Company's announcement dated 12 February 2026 here) and provide early evidence supporting the durability of the therapy's effects. Improvements across multiple independent endpoints remain consistent with earlier observations, while control animals continue to exhibit expected age-related decline.

The SLAB study remains ongoing, with all dogs continuing to be actively monitored and evaluated. The trial is expected to continue for a further four months, with completion anticipated at the end of July 2026. Additional analyses, including methylation clock (biological age) assessment and muscle histology, are in progress and are expected to provide further mechanistic and quantitative insight into the therapy's impact.

Dr Eric Leire, Chief Executive Officer of Genflow said: "These follow-up observations are important as they extend our understanding beyond initial efficacy and into persistence of effect. The consistency of improvements across multiple functional endpoints, together with the continued absence of safety concerns, strengthens our confidence that SIRT6 gene therapy is delivering a sustained biological impact.

Based on the data observed to date, we believe this supports the positioning of our SIRT6 platform as a potentially disease-modifying approach to addressing age-related decline in companion animals. As the study progresses, we continue to engage with prospective partners across animal health to explore licensing, co-development, and commercialisation opportunities."

Further updates will be provided as additional data becomes available.

Yes indeed Perseverance, it worked like magic in mice and the preliminary efficacy data from the Dog Trial was stunning, and much stronger and conclusive than Eric had expected and so every chance comprehensive endpoint data will follow suit, and so translation to human could be highly likely.

It was extremely intetesting that Eric stated in his Oxford University Longevity presentation that it was "people from Merck" who had suggested Genflow should look into Sirt6's potential for Dog healthspan, and so every chance they could be one of the players who've signed Confidential Disclosure Agreements. Merck Animal Healthcare ( a division of Merck ) is the leading Animal Healthcare Company in the world behind Zoetis, both of which were at the JP Morgan HealthCare Conference where Genflow attended in January, and so any deal with Merck Animal Healthcare on the Dog Therapy would obviously be company defining , and would also provide the transition to human healthspan through Merck themselves, one of the top 5 Major Pharma's in the world.

A lucrative commercial licensing deal on the Dog Trial is likely to propel Genflow from small cap to mid cap, and the sky would be the limit thereafter, if a Major Pharma wanted to take Genflow's Sirt6 Gene Therapy Platform to PoC in human. Gla holders;-)

UP 12% and mostly buys & Bed & Isa's imho...Excitement building in anticipation of incoming game changing news!!! Gla holders:-)

Nice one Porter, Onwards and UPwards!!! Gl :-)

Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines

Apr 6, 2026, 20:06

Mergers and acquisitions (M&A) in the pharma and biotech sector have accelerated notably year to date, building on a rebound in 2025.

A recent surge in dealmaking underscores the industry’s focus on portfolio expansion and continuous pipeline innovation, alongside a growing emphasis on AI-driven drug discovery. Oncology and immuno-oncology companies have always been at the top of acquisition targets. Major players are actively pursuing licensing agreements and collaborations around promising drugs and candidates to further strengthen and diversify their core portfolios.

Quick Take on Recent M&A Deals

..........

Road Ahead in 2026

Consolidation remains a key theme as companies seek to offset patent cliffs and diversify revenue streams. Acquisitions offer a faster, less risky route than in-house development, especially as innovation cycles shorten.

With strong cash reserves and increasing adoption of advanced technologies like AI, M&A activity is expected to remain robust through 2026. Smaller biotechs, often constrained by funding, will likely continue to be prime acquisition targets, further fueling deal momentum.

Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines — TradingView News hTtps://share.google/EvXa9wAGt9MdugspA

Ii Porter, online it states it could take several days to be executed and therefore the sp could fluctuate ( obviously big time if news lands during that time), and so I insisted I wanted to do it over the phone, hence the hour pluse it took, and even then they were trying to persuade me to do it online and said they couldn't execute themselves , until I agreed to the 2 x £49 fees whereby they eventually phoned it through to the back office, where the trader was able to do it there and then. Very stressful but very releived, especially as news could land tomorrow, but now hope it doesn't until your Bed & Isa is sorted. Gl ;-)😬😬😬

Lol Porter, a very stressful experience, at one point I thought they had sold them and we're telling me they couldn't by them back, but the traders in the back office got it sorted, and so relieved it went through despite costing me 8,972 shares!!! Gl ;-)

Ps my Bed & Isa trades have just popped UP!!! Gl :-)

Lol Porter, it's just taken me 1hr 3 mins to get mine done by phone, 855k plus sold and bought back in my Isa with a lot less given 2 charges of £49 quid plus for the 2 trades, otherwise they couldn't guarantee it would happen on the same day and could take a couple of days, which wouldn't have been ideal if game changing news lands tomorrow. My Isa is now fully loaded with Genflow shares accumulated over the last couple of years or so. Excitement building, potential transformational game changing news imminent!!! Gl ;-)))

Yes indeed Steg, potential transformational game changing news imminent, although hopefully not tomorrow as i've a tranche of Genflow shares sitting in my trading account ready to Bed & Isa first thing. Excitement building with every chance of a multi-bag coming this way on stellar results from the Dog Trial along with a lucrative commercial licensing deal or two. Gl ;-))))

TR1's and/or Game Changing news at anytime. Gla Holders:-)

Funding strategy reflects sector dynamics

The dual funding announcement illustrates a common pattern in early-stage biotech financing, where companies combine market-based capital raises with institutional or government-backed grants. This hybrid model helps balance financial flexibility with shareholder considerations.

In recent years, European funding bodies have shown increased willingness to support innovative healthcare projects, particularly those addressing long-term demographic challenges such as ageing populations. The €4 million grant secured by Genflow Biosciences reflects this broader policy direction.

At the same time, smaller equity raises remain a practical tool for maintaining operational continuity, especially in volatile market conditions where larger fundraising rounds may be more difficult to execute.

Advancing research milestones

With additional capital in place, Genflow Biosciences is expected to continue advancing its gene therapy programmes through key preclinical stages. These steps are critical in establishing safety and efficacy profiles before progressing to clinical trials.

The company’s focus on ageing-related diseases places it at the intersection of several high-growth areas within biotechnology, including genomics, regenerative medicine, and personalised therapies.

€4 million grant reinforces scientific credibility

The receipt of the first tranche of a €4 million grant introduces a non-dilutive funding element that is particularly valuable in the capital-intensive biotech sector. Grant funding allows companies to progress research without issuing additional shares, thereby limiting shareholder dilution.

Such grants are typically awarded following rigorous evaluation processes, suggesting that Genflow Biosciences’ research into gene-based interventions for ageing-related conditions has met defined scientific and innovation criteria.

The funding is expected to support further development of the company’s lead programmes, which focus on addressing biological mechanisms linked to ageing. This area has attracted increasing attention in recent years, with advances in genomics and molecular biology opening new pathways for therapeutic intervention.

Positioning within the longevity biotech space

Genflow Biosciences operates within the emerging longevity biotechnology segment, where companies are seeking to tackle the root causes of age-associated diseases rather than individual symptoms. This approach aligns with a broader shift in medical research toward preventative and regenerative therapies.

Historically, breakthroughs in this field have been closely tied to advancements in gene editing and delivery technologies. The ability to modify or regulate gene expression has created opportunities to target conditions that were previously considered difficult to treat.

Against this backdrop, Genflow Biosciences is positioning itself among a cohort of biotech firms exploring how genetic interventions can extend healthy lifespan. The combination of equity funding and grant support provides a foundation for continued progress as the company moves through its exciting development roadmap.